Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2018-12-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于增加募集资金投资项目支付结算方式并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding changes in the payment settlement method for investment projects funded by raised capital and the replacement of funds with an equivalent amount from raised capital. It details the approval process, the use of funds, and opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather discusses financing and capital usage adjustments. It is not a full financial report, earnings release, or management report. The content fits best under Capital/Financing Update (CAP) as it relates to changes in the use and management of raised funds and capital structure.
2018-12-11 Chinese
第二届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Xiamen Aide Biomedical Technology Co., Ltd. It details the approval of changes related to the use of raised funds, project investment delays, and payment settlement methods. The document is short (1428 characters) and primarily announces decisions made in a board meeting rather than providing detailed financial data or a full report. It references other announcements published on the designated disclosure website for more details. This fits the profile of a Regulatory Filing (RNS) as it is a formal regulatory announcement about corporate governance decisions and fund usage changes, but not a full financial report or capital update document itself.
2018-12-11 Chinese
关于召开2018年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2018 second extraordinary general meeting of shareholders for Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It includes information about the meeting date, location, voting procedures (both in-person and online), registration methods, agenda items, and related attachments such as proxy forms and voting instructions. The document does not contain financial statements or results but is focused on informing shareholders about the meeting and how to participate and vote. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to provide information and request votes for meetings. The document length is 4240 characters, which is consistent with a detailed meeting notice rather than a full report or announcement of voting results. Therefore, the correct classification is PSI with high confidence.
2018-12-11 Chinese
关于变更部分募集资金用途及募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding changes in the use of part of its raised funds from an initial public offering (IPO) and delays in investment projects funded by those raised funds. It includes specifics about the original fundraising, the amounts involved, the projects affected, reasons for changes, and approvals from the board, independent directors, supervisory board, and the sponsoring institution. The document focuses on the reallocation of IPO proceeds and project delays, which are typical of capital or financing updates. There is no indication that this is a full annual or interim report, audit report, earnings release, or other types of filings. The document is not a simple announcement of a report publication but a substantive update on capital use and project status. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-12-11 Chinese
中信证券股份有限公司关于公司变更部分募集资金用途及募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding changes in the use of proceeds from a company's initial public offering (IPO) and the postponement of investment projects funded by the raised capital. It includes specifics about the original fundraising, the adjusted use of funds, project descriptions, investment amounts, reasons for changes, and approvals from the board, supervisory committee, independent directors, and the sponsor institution. The document references regulatory approvals and compliance with stock exchange rules. It is not a simple announcement but a comprehensive verification opinion and detailed explanation related to fundraising use and project delays. This fits the category of a Capital/Financing Update (CAP), as it deals with changes in fundraising use and investment projects funded by raised capital, rather than a full annual or interim report, audit report, or other categories.
2018-12-11 Chinese
信息披露管理制度（2018年12月）
Governance Information Classification · 95% confidence The document is titled "信息披露管理制度" which translates to "Information Disclosure Management System" for 厦门艾德生物医药科技股份有限公司. It extensively discusses the company's policies and procedures for information disclosure, including legal and regulatory compliance, responsibilities of directors and management, types of reports (annual, interim, quarterly, and temporary reports), disclosure of transactions, related party transactions, major litigation, and other significant events. The document references Chinese securities laws, Shenzhen Stock Exchange rules, and China Securities Regulatory Commission requirements. It is a comprehensive internal governance document outlining how the company manages and discloses information to the public and regulators. It does not contain actual financial statements, earnings data, audit opinions, or voting results. It is not a report of financial results, audit, or meeting materials but rather a governance and compliance manual related to disclosure practices. Therefore, the document best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2018-12-11 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.